Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

The cash price of the popular weight-loss drug Wegovy was lowered by 30% on Monday, now priced at $349, down from $499.

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

WASHINGTON – On November 6, 2025, U.S. Senators Amy Klobuchar (D-MN) released the following statement in response to Eli Lilly and Novo Nordisk’s newly negotiated prices for weight loss drugs for ...

Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the U.S.